Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
about
Modes of resistance to anti-angiogenic therapyAnti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapyTumor refractoriness to anti-VEGF therapyMarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumorsEvaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imagingOptimal combination of antiangiogenic therapy for hepatocellular carcinomaCirculating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlookPharmacogenetic biomarkers for the prediction of response to antiangiogenic treatmentResistance and escape from antiangiogenesis therapy: clinical implications and future strategiesMechanisms of evasive resistance to anti-VEGF therapy in glioblastomaCirculating biomarkers in advanced renal cell carcinoma: clinical applicationsPhase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancerLymphangiogenesis is required for pancreatic islet inflammation and diabetesIdentification of novel therapeutic targets in microdissected clear cell ovarian cancersAccelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesisTumor angiogenesisRapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.Angiogenic inhibition in high-grade gliomas: past, present and future.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapySunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignanciesAdverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.Phase I study of pazopanib plus TH-302 in advanced solid tumors.Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.Local acting Sticky-trap inhibits vascular endothelial growth factor dependent pathological angiogenesis in the eye.CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.Molecular mechanisms of resistance to tumour anti-angiogenic strategiesAnti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.Pharmacologic modulation of niche accessibility via tyrosine kinase inhibition enhances marrow and thymic engraftment after hematopoietic stem cell transplantation.Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast CancerCytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignanciesPharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells
P2860
Q24608005-86863BFC-41C2-4F3A-A2E0-EC6EA72268A2Q24655930-44A32DD5-5990-42B1-A7F8-D6007E546E80Q26747678-E3D3CF00-56D6-4D4C-971F-F967CE880125Q26752752-DAC65F0B-AD5C-4F2C-9DAE-6176FEF9A5DDQ26773795-4058B333-180A-413D-B850-EDAF804B0441Q26783895-549AE42F-313F-4F4D-B498-8194A4850E93Q26799458-000C0B07-C237-420F-989B-D2C9B205D93FQ26823035-0541827A-C870-4E60-BD8F-43FD29377D03Q26996793-D8877D90-AEDB-46DB-94CF-7FBA6D810E20Q27016629-72DB0D37-08ED-4D96-848F-9CF0BEEC192AQ27021470-124105B5-4376-41F2-A9C6-BD64341AFA6BQ27023770-F0D8BE77-CAA6-441A-9CD3-3189B2EAB771Q27320322-D3372BE1-147A-4796-BBD9-3DCE3CE3E8F2Q28742322-285FA5DF-F5E9-40A8-BFBC-130DEDEE90D5Q28742873-F92D85DE-3C51-4819-B1A6-0A7FF4F7DB31Q29614537-29DFB17E-D06F-475E-BAB2-EA311A976A45Q29614938-9A31BE02-3A17-41BB-A9D0-68623E33436AQ30438696-4A4D741D-A254-46A4-8EEB-603F49FC9314Q30455596-DC7B8DF0-6D33-4866-A170-27C057C6488CQ30455612-F50C3CD0-A4D5-40C4-9C9D-706230B12937Q33394774-26EE4592-FCD4-471E-9CEC-A574A0149B7EQ33405318-951E9207-46CD-4C25-A3CC-21C6EB92A263Q33410375-F6FAF2CF-1E59-418C-88AA-719E197994BAQ33424257-D246CC4C-5790-409D-BCC7-E40B6DCC412CQ33429309-D6CA7229-A9EB-418B-951E-D9D42EF782DBQ33439635-7774279A-6E92-4A55-BE4D-1D5CD2340B77Q33457195-F432742E-740B-42DE-B851-9FE020BD1C4CQ33616649-DE4EBCB6-AB12-4390-91D9-4703A72F8F32Q33623357-D6E9E481-9D5B-4787-97BF-DB34BFE88986Q33630819-843213FA-3993-43A2-B2E0-5169E7D925B7Q33718025-387EDD1B-310F-47D4-B061-60ED4B6F439CQ33770680-9A4DBEDB-A6AC-40F5-BEBF-4FBF598AA2B8Q33845524-43C38F6D-FD9E-4773-A48D-D5345002FC46Q33871518-F3D1DD05-D75A-47A0-82F0-93E32C61B365Q33899627-89D3D8F4-10A6-4F22-9207-B189EAFC28FDQ34080323-E35F654B-40F5-455D-B33B-04EAA6D6115BQ34340390-6B6001B4-36A5-446D-8103-DF7ED298FD66Q34356881-77ADB54B-4039-4F54-8A53-6D4B8A0ABA98Q34468729-29CBD126-5294-45D3-8D23-FD1E1125D6ADQ34471954-FEB73BAC-CD3D-422C-A7DA-0E6876172EB7
P2860
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Multiple circulating proangiog ...... relate with antitumor efficacy
@ast
Multiple circulating proangiog ...... relate with antitumor efficacy
@en
type
label
Multiple circulating proangiog ...... relate with antitumor efficacy
@ast
Multiple circulating proangiog ...... relate with antitumor efficacy
@en
prefLabel
Multiple circulating proangiog ...... relate with antitumor efficacy
@ast
Multiple circulating proangiog ...... relate with antitumor efficacy
@en
P2093
P2860
P356
P1476
Multiple circulating proangiog ...... relate with antitumor efficacy
@en
P2093
Anthony J Mutsaers
Christina R Lee
James G Christensen
Robert S Kerbel
P2860
P304
17069-17074
P356
10.1073/PNAS.0708148104
P407
P50
P577
2007-10-17T00:00:00Z